Incannex Healthcare Limited
IXHL · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.03 | -0.00 | 130.43 |
| FCF Yield | -168.48% | -33.81% | -39.09% | -0.77% |
| EV / EBITDA | 0.15 | -1.52 | -0.50 | -110.55 |
| Quality | ||||
| ROIC | -167.79% | -383.29% | -63.89% | -41.04% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.27 | 0.86 | 0.22 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.34% | -45.70% | -25.14% | -70.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 0.20 | 1.59 | 2.54 |
| Interest Coverage | -78.51 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 19,633.60 | 203,475.33 | 0.00 | -75,195.69 |